Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk steps up ad spend to keep the weight-loss crown
Novo Nordisk (NYSE:NVO) appears to be taking a no-holds-barred approach to becoming the number one weight-loss drug in the US after it emerged that an ad for one of its key products was viewed nearly 2 billion times between June 3 and June 25, making it the third most-watched commercial during that period. The Wall Street Journal, citing iSpot.tv, reported the Wegovy ad, titled "Discover the Power", was shown 6,271 times and cost an estimated $42 million in national airtime.
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Novo Nordisk's flagship obesity care treatment, Wegovy, recently received approval in China. Obesity is a big medical issue in China, estimated to affect hundreds of millions of people.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
Novo Nordisk makes impairment loss of $816 mln in Q2
Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.
Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing
Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.
Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Novo Nordisk gains approval in China for blockbuster drug Wegovy. More than 11% of all adults in China live with diabetes - more than any other country in the world. Both Eli Lilly and Novo Nordisk are disrupting the diet industry with their GLP-1 drugs, offering the potential for significant growth in the future.
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Novo Nordisk Rises as Wegovy Is Approved in China
American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) rose Tuesday on the New York Stock Exchange (NYSE) after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China.
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Novo Nordisk gains approval to sell weight-loss drug Wegovy in China
Novo Nordisk has gained approval to start marketing its blockbuster weight-loss drug Wegovy in China, opening the door for the Danish pharmaceutical giant to further boost sales of the medicine that has transformed it into Europe's most valuable company.
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
Novo Nordisk (NYSE: NVO ) stock rose on news that China has approved its weight loss drug Wegovy and that the drugmaker will invest $4.1 billion into expanding its U.S. production capacity. The expansion will be built in North Carolina and is part of a $11 billion global production push.
